Volume 7, Issue 3 (9-2013)                   payavard 2013, 7(3): 177-187 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Abbasi S, Ajdari A, Mohammadi S. The Relationship Between FLT3 Mutations And Complete Remission Of AML Patients Referring To Shariati Hospital. payavard 2013; 7 (3) :177-187
URL: http://payavard.tums.ac.ir/article-1-5057-en.html
1- Assistant Professor, Medical Biotechnology Department, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran , Abbasisk@tums.ac.ir
2- Master of Science in Hematology, Hematology and Blood Bank Department, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran
Abstract:   (8939 Views)

Background and Aim: FLT3 gene is a member of class III receptor Tyrosine Kinase, which is expressed in most patients with acute myeloid leukemia (AML). Mutations of FLT3 such as Internal Tandem Duplication (ITD) and point mutation of the D835 are the most common genetic defects in myeloid leukemia. These two mutations in patients with MLA and their effect on survival rate were studied for the first time in Iran.

Materials and Methods: DNA was extracted from the blood or bone marrow samples of 100 patients with AML from October 2008 to September 2009. For further analysis, PCR was performed to determine the prevalence of these mutations and their association with prognosis. Moreover, t and x2 statistical tests were applied for data analysis.

Results: According to the results, 15% of patients revealed FLT3-ITD mutations and 8% showed mutation of D835 in FLT3 gene. In terms of achieving complete remission (CR), patients with mutation of ITD had more chance than those without such mutation (83.5% versus 53.3%). The white blood cell count was significantly higher in the ITD+ (mean = 73,646/ml) than ITD- patients (mean = 26,580/ml).

Conclusion : The results indicate that FLT3-ITD mutations may reduce the chances of Complete Remission (CR) in patients however, FLT3-ITD mutation is an important factor in selecting appropriate treatment.

Full-Text [PDF 378 kb]   (6254 Downloads)    
Type of Study: Original Research | Subject: Hospital Managment
ePublished: 1399/07/23

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by: Yektaweb